43 papers in the library · 67 citations · publishing 2020-2026
medRxiv Preprint Server January 30, 2024 Lauren N. Swanson, Lila S. Jones, Jose Muñoz Aycart et al. preprint
Objective To evaluate the effectiveness of repeated at-home ketamine treatments for depression, generalized anxiety, and social anxiety and assess safety in terms of adverse effects and tendency towards long-term use.
medRxiv Preprint Server December 1, 2023 Brandon Taraku, Joana R Loureiro, Ashish K Sahib et al. 1 citation preprint
Dysfunctional reward processing in major depressive disorder (MDD) involves functional circuitry of the habenula (Hb) and nucleus accumbens (NAc). Ketamine elicits rapid antidepressant and alleviates anhedonia in MDD. To clarify how ketamine perturbs reward circuitry in MDD, we examined how serial ketamine infusions (SKI) modulate static and dynamic functional connectivity (FC) in Hb and NAc...
medRxiv Preprint Server July 3, 2023 Eric A. Miller, Houtan Totonchi Afshar, Jyoti Mishra et al. preprint
Background Ketamine helps some patients with treatment resistant depression (TRD), but reliable methods for predicting which patients will, or will not, respond to treatment are lacking.
medRxiv Preprint Server June 28, 2023 Mohammad Ali Shenasa, Houtan Totonchi Afshar, Eric A. Miller et al. preprint
Background The antidepressant effects of ketamine and repetitive transcranial magnetic stimulation (rTMS) are hypothesized to rely on mechanisms of long-term-potentiation and synaptic plasticity. Cannabis, via activation of CB1 receptors has been shown to impair synaptic plasticity, suggesting that cannabis use might moderate the antidepressant effects of ketamine and/or rTMS.
medRxiv Preprint Server April 28, 2023 Theresa R. Lii, Ashleigh E. Smith, Josephine R. Flohr et al. 28 citations preprint
Abstract BACKGROUND Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials. METHODS In a triple-masked, randomized, placebo-controlled trial, 40 adult patients with major depressive disorder were randomized to a single infusion of ketamine (0.5 mg/kg) or placebo (saline) during anesthesia as usual for routine...
medRxiv Preprint Server January 3, 2023 Bessel Van der Kolk, Julie B. Wang, Rachel Yehuda et al. 2 citations preprint
In recent years there has been a resurgence of interest in the therapeutic potential of psychedelic substances such as 3,4-methylenedioxymethamphetamine (MDMA). This renaissance of psychedelic studies opens the door for a new paradigm in psychiatric medicine: drug-facilitated psychotherapy. In this study we report the findings of a randomized, double-blind, placebo-controlled, multi-site Phase...
medRxiv Preprint Server April 23, 2022 Alexia G. Aguilar, Burke A. Beauregard, Christopher P. Conroy et al. 2 citations preprint
Background Ketamine and esketamine are efficacious for treatment resistant depression. Unlike other antidepressants, ketamine and esketamine lack a therapeutic delay and do not increase risk for suicidal thoughts and behaviors in adolescents and young-adults. Esketamine gained FDA approval in March of 2019.
medRxiv Preprint Server September 23, 2021 Nirmaljot Kaur, Siva Naga S. Yarrarapu, Abhishek R. Giri et al. preprint
Background Ketamine, a dissociative anesthetic, induces remission of depression by antagonizing glutaminergic NMDA receptors. Ketamine has been used previously in outpatient setting for treatment-resistant depression, but we showcase its utility in depression management at the Intensive Care Unit (ICU).
medRxiv Preprint Server July 7, 2021 Or Duek, Yutong Li, Ben Kelmendi et al. 8 citations preprint
NMDA receptor antagonists have a vital role in extinction, learning, and reconsolidation processes. During the reconsolidation window, memories are activated into a labile state and can be stored in an altered form. This concept might have significant clinical implications in treating PTSD. Using amygdala activity as a major biomarker of fear response, we tested the potential of a single...
medRxiv Preprint Server June 13, 2021 Rui Du, Kun Niu, Guofang Lu et al. preprint
The aim of this systematic review and meta-analysis was to examine the efficacy, anti-effect of ketamine (intervention) for post-traumatic stress disorder (PTSD) patients during analgesia proceeding and mental illness treatment methods, in comparison with control (midazolam, opioid, saline or placebo). The bibliographic databases Cochrane, Embase, Pubmed and Web of Science were searched from...
medRxiv Preprint Server April 20, 2021 Anand S. Patil, Ahish Chitneni, Suhani Dalal et al. preprint
Background This systematic review aims to review clinical studies on the use of ketamine infusion for patients with treatment-resistant Complex Regional Pain Syndrome (CRPS).
medRxiv Preprint Server April 10, 2021 Agnes Norbury, Sarah B. Rutter, Abigail B. Collins et al. 1 citation preprint
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD). Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants...
medRxiv Preprint Server February 22, 2021 Jessica R. Gilbert, Christina S. Galiano, Allison C. Nugent et al. preprint
The glutamatergic modulator ketamine rapidly reduces depressive symptoms in individuals with treatment-resistant major depressive disorder (MDD) and bipolar disorder. While its underlying mechanism of antidepressant action is not fully understood, modulating glutamatergically-mediated connectivity appears to be a critical component moderating antidepressant response. This double-blind,...
medRxiv Preprint Server February 21, 2021 Jinsong Tang, Qiuxia Wu, Chang Qi et al. preprint
Background A version of ketamine, called Esketamine has been approved for treatment-resistant depression (TRD). Ketamine (“K powder”), a “dissociative” anesthetic agent, however, has been used non-medically alone or with other illicit substances. Our previous studies showed a link between non-medical ketamine use and brain structural and functional alterations. We found dorsal prefrontal gray...
medRxiv Preprint Server December 7, 2020 Vasileia Kotoula, Argyris Stringaris, Nuria Mackes et al. 9 citations preprint
Ketamine as an antidepressant improves anhedonia, a pernicious symptom of depression as early as 2h post-infusion. The effects of ketamine on anhedonia are thought to be exerted via actions on reward-related brain areas—yet, these actions remain largely unknown. This study examines ketamine’s effects during the anticipation and receipt of an expected reward, after the psychotomimetic effects of...
medRxiv Preprint Server November 26, 2020 Giulia Bommarito, Anjali Tarun, Younes Farouj et al. 7 citations preprint
Background Modifications in brain function remain relatively unexplored in progressive multiple sclerosis (PMS), despite their potential to provide new insights into the pathophysiology of this disease stage.
medRxiv Preprint Server August 31, 2020 Steven Pennybaker, Brian J Roach, Susanna L Fryer et al. preprint
Background Ketamine is a rapid-acting treatment for patients with treatment refractory depression (TRD), however treatment responses are often transient and ketamine’s antidepressant action lacks robust clinical durability. Little is known about which patient characteristics are associated with faster or more durable ketamine responses. Ketamine’s antidepressant mechanism is proposed to involve...
medRxiv Preprint Server April 10, 2020 Chadi G. Abdallah, Kyung-Heup Ahn, Lynnette A. Averill et al. 1 citation preprint
Over the past decade, various N-Methyl-D-Aspartate modulators have failed in clinical trials, underscoring the challenges of developing novel rapid-acting antidepressants based solely on the receptor or regional targets of ketamine. Thus, identifying the effect of ketamine on the brain circuitry and networks is becoming increasingly critical. In this longitudinal functional magnetic resonance...